Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | -3.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.78 | N/A | -3.86% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism regarding their research initiatives. They are focused on long-term growth despite the current financial challenges.
Management highlighted ongoing research efforts and future potential despite current losses.
They emphasized a commitment to advancing their pipeline.
Nektar Therapeutics reported a loss that was slightly worse than expected, but the stock rose 1.79% following the earnings announcement. Investors may be encouraged by management's focus on ongoing research and future potential, which could signal confidence in the company's long-term strategy despite current losses.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
May 4, 2020